Document is current
Any future updates will be listed below
-
Authors
Khatri, Vaseem M.
Aboujaoude, Michael
Karapetyan, Lilit
Tarhini, Ahmad A.
Brohl, Andrew S.
Eroglu, Zeynep
Markowitz, Joseph
Rayn, Kareem
Khushalani, Nikhil I.
Wuthrick, Evan J.
Yu, H. Michael.
Oliver, Daniel E.
Ahmed, Kamran A.
- License Information
-
More Information
Article History
Received: 29 January 2026
Accepted: 4 March 2026
First Online: 9 March 2026
Declarations
:
: Lilit Karapetyan has received research support from Iovance and Valar Labs and travel support from Immatics. Andrew Brohl has received research funding to the institution from Merck and is on the advisory board of Deciphera. Joseph Markowitz has received research funding to the institution from TuHURA Biosciences and Merck. Nikhil Khushalani is on the advisory boards of Regeneron, Merck, Replimune, Immunocore, Iovance Biotherapeutics, Novartis, IO Biotech, MyCareGorithm, and HUYABIO International, has received travel support from Castle Biosciences and Regeneron, is on the data safety monitoring board of Incyte and AstraZeneca, is on the Scientific Advisory Board of T-Knife Therapeutics, is on the study steering committee of BMS, Nektar, Regeneron, and Replimune, holds common stock in Bellicum Pharmaceuticals, and Amarin, and has received research funding to the institution from BMS, Merck, Regeneron, Replimune, GSK, Celgene, Novartis, IDEAYA Biosciences, Modulation Therapeutics, and HUYABIO International. Hsiang-Hsuan Michael Yu has received speaker’s honoraria from BrainLab and is on the advisory boards of Novocure and Abbvie. Kamran A. Ahmed has received research funding from Bristol-Myers Squibb, Eli Lilly, and Genentech.
